New advances in PET imaging will be presented at the Turku PET Symposium 2022. The event focuses on PET imaging in diagnostics and therapy and takes place 3-6 June in Turku, Finland.
At this symposium, new data around PET tracers for the incretin hormone receptors will be presented. The incretin hormones and their receptors are crucial for glucose homeostasis, food intake, and energy metabolism. In the poster ‘Preclinical and clinical PET imaging of glucagon-like peptide 1 receptor in brain’ the binding of a triple incretin agonist for GIP, GLP-1 and glucagon in the brain was evaluated using a PET tracer for the GLP-1 receptor. This tracer has previously supported the investigation of receptor occupancy of anti-diabetic drugs in both pre-clinical and clinical drug development. The presented work has been performed in collaboration between Uppsala University, Sanofi and Antaros Medical.
Title: Preclinical and clinical PET imaging of glucagon-like peptide 1 receptor in brain
Poster number: P28
Authors: Velikyan I, Bossart M, de Berardinis N, Sundin A, Eriksson B, Wagner M, Eriksson O
Further, new data originating from an Antaros Medical imaging method study is presented. The study investigates the test-retest repeatability of combined PET/MRI-derived free fatty acid uptake and tissue blood flow readouts in subjects with type 2 diabetes. The current poster presents an improved radiometabolite analysis method for [18F]FTHA in blood. The work has been performed in collaboration between University of Turku and Antaros Medical.
Title: Improved radiometabolite analysis method for [18F]FTHA in human plasma
Poster number: P5
Authors: Aarnio R, Kirjavainen A, Forsback S, Kalliokoski K, Nuutila P, Laitinen I, Haaparanta-Solin M
Olof Eriksson, Senior Director PET Imaging at Antaros Medical and Associate Professor at Uppsala University, will also present around ‘New ways of understanding the complex biology of diabetes using PET’ on Monday June 6 @ 11.00-11.45.
Antaros Medical and PET imaging
PET tracers have emerged as important biomarkers supporting drug development due to their ability in understanding both the drug and its target as well as to provide important insights into human biology quantitatively at a receptor level. Antaros Medical has an extensive experience of supporting pharmaceutical companies with insights for drug development decisions and has a set-up for bringing new imaging biomarkers, including novel PET-tracers, into clinical use for drug development. We also provide insights through established PET tracers such as FDG-, FTHA-, 15O-PET.
Recently the company developed a set of proprietary PET-tracers targeting the glucagon and gastric inhibitory polypeptide (GIP) receptors. A powerful tool set, together with the PET tracer targeting the glucagon like peptide-1 (GLP-1) receptor, to be used in the metabolic drug development field where both bimodal and trimodal incretin-based therapies are progressing fast.
Antaros Tracer, a sister company to Antaros Medical, has a continued focus on developing PET tracers for inflammation, fibrosis and immunology/immuno oncology, where there is a high unmet need for new therapies and understanding. The research activity in this field is high, trying to increase the understanding of the underlying mechanisms and to develop targeted and effective medicines to improve the outcome for patients.
The efforts put into the development of new PET tracers aim to support the selection and development of drug candidates, especially during early clinical development stages. This will save time and cost and can bring new medicines to patients faster.